Weight loss injections on the NHS when you have diabetes: making the right call

The NHS routes available, and where diabetes changes the picture

The NHS offers two main clinical pathways for weight loss injections. Semaglutide (Wegovy) is available via specialist weight management services under NICE's appraisal TA875, with strict criteria: adults with a BMI of 35 or above and at least one weight-related condition, used within a multidisciplinary specialist service for a maximum of two years. Tirzepatide (Mounjaro) sits under NICE appraisal TA1026, now being rolled out through NHS primary care in phased cohorts, currently prioritising adults with a BMI of 40 or above alongside four or more specific conditions (including type 2 diabetes). A second cohort covering BMI 35–39.9 became active in June 2026.

Having type 2 diabetes does help you meet the comorbidity threshold for these NHS pathways. But meeting a threshold does not guarantee access: your GP surgery's participation in the new prescribing arrangement is voluntary, waiting lists for specialist services are often long, and availability differs across NHS trusts and regions. If you want to understand how the weight loss injection NHS process works in practice, including what criteria apply and how commissioning is expanding, that picture is still evolving.

What changes most when diabetes is part of your history is the monitoring conversation. A prescriber who reviews your case needs to know about your existing diabetes regimen (particularly if you take insulin or a sulphonylurea) because GLP-1 medicines slow gastric emptying and reduce appetite in ways that can affect blood glucose, sometimes meaningfully. That is not a reason to avoid them; it is a reason to be reviewed carefully before starting.

Tirzepatide or semaglutide: how the diabetes context shapes the choice

Both medicines started life in diabetes care before their weight management licences arrived, so the evidence base in people with type 2 diabetes is substantial. Tirzepatide (Mounjaro) activates both GIP and GLP-1 receptors, making it the only dual-agonist weight loss medicine licensed in the UK. In the SURMOUNT programme, involving thousands of adults across multiple trials, tirzepatide produced average body weight reductions in the range of 15–21% at higher doses over 72 weeks, with people with type 2 diabetes in SURMOUNT-2 showing meaningful results alongside improved HbA1c. The SURMOUNT-1 data published in the New England Journal of Medicine gives the clearest picture of what the 15mg dose can produce over time.

Semaglutide (Wegovy) is a GLP-1 receptor agonist, well established in type 2 diabetes care through its diabetes-licensed sibling, Ozempic. Wegovy's weight management licence is separate; Ozempic is not licensed for weight loss and should not be sought for that purpose. If you want to explore the clinical detail on both medicines side by side, our overview of licensed weight loss injections in the UK covers the evidence in full.

A brief practical note: if you are thinking about starting or switching treatment and you're reading this around a bank holiday, it is worth knowing that our order cut-off is 12pm on working days, a Monday order after a long weekend is often the easiest way to get things moving without delay.

What is still uncertain, and who to speak to

What is known is that both medicines have a strong evidence base for people with obesity and type 2 diabetes, that the NHS is actively expanding access to weight loss injections, including how eligibility criteria and commissioning arrangements continue to develop, and that private prescription through a regulated pharmacy is a legal and clinically supervised alternative for those who do not meet NHS thresholds or cannot wait. What is genuinely uncertain for any individual is whether the medicines are appropriate given your full diabetes history, your current prescriptions and any other conditions you have.

Some situations require extra care. If you have a history of pancreatitis, have been told you have diabetic retinopathy, or are on multiple diabetes medicines, those details belong in your clinical consultation. The NHS England guidance on weight management injections sets out the clinical considerations clearly, including advice for people on existing treatments.

Pregnancy and breastfeeding are a firm boundary: these medicines are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. If there is any chance you could become pregnant while on treatment, a prescriber will discuss contraception with you. Women taking the oral contraceptive pill alongside tirzepatide are advised to add a non-oral method for the first four weeks of treatment and for four weeks after any dose increase, because tirzepatide's effect on gastric emptying can reduce how reliably the pill is absorbed. Your prescriber or GP will guide you on when it might be safe to restart treatment after any of these situations.

If you are unsure whether NHS criteria apply to you, or if you have been turned down and want to understand your private options, our prescribers review each case individually. You can read more about how type 2 diabetes affects eligibility for weight loss injections on the NHS, or find out whether you may qualify for an NHS approved weight loss injection and what that approval process involves. If you have questions specifically about how a diabetic injection for weight loss works within NHS prescribing, including which medicines are covered and how diabetes history affects your pathway, that detail is covered separately. Specific questions about your own health are best put directly in a consultation, where a GPhC-registered Independent Prescriber reads your answers the same day, a real clinician, not an automated system. Speak to our prescribers to get a clear picture of where you stand.